Examination about safety and the effectiveness when we switched from a GnRH antagonist to a GnRH agonist at the time of prostate cancer hormonal therapy introduction

Examination about safety and the effectiveness when we switched from a GnRH antagonist to a GnRH agonist at the time of prostate cancer hormonal therapy introduction - Clinical trial when I switched from a GnGH antagonist to a GnRH agonist at the time of prostate cancer hormonal therapy introduction

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000011379

Enrollment

Registered

2013-08-06

Start date

2013-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate Cancer

Interventions

None listed

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: 1.The patient pathologically diagnosed as a prostatic cancer 2.The first patient to receive an hormonal therapy

Exclusion criteria

Exclusion criteria: 1.The patient who has the condition by metastasis 2.Gleason Score8over 3.Prostate volume 50cc over 4.The patient who judged that a doctor in charge was unsuitable

Design outcomes

Primary

Measure	Time frame
Changes in LH and testosterone level after switch the GnRH agonist	—

Secondary

Measure	Time frame
Changes in LH, testosterone, PSA. FSH level after administration of the GnRH antagonist	—

Countries

Japan

Contacts

Public ContactMasaaki Yanishi

Kansai Medical University Urology

masaaki.yanishi@gmail.com072-804-0101

Outcome results